###### Strengths and limitations of this study

-   A recent Cochrane systematic review of cough medicines found no good evidence for or against the effectiveness of over-the-counter medications in acute cough.

-   This is one of the largest multiple dosing, multicentre, randomised, controlled trials in participants with cough to date, and the first to recruit participants seeking cough medicines at pharmacies and is therefore more likely to represent the broader population with acute cough due to upper respiratory tract infection.

-   Participants were unselected for the category of cough, and included a broad range of participants with self-reported dry, chesty and tickly cough.

-   The study was single-blinded because an active control, simple linctus, was used as the comparator but it is possible that there may have been greater differences in efficacy outcome measures if an inactive placebo had been used.

-   Our findings highlight the challenges of evaluating cough medicines in a rapidly improving condition and will facilitate the design of future studies of acute cough.

Introduction {#s1}
============

Approximately one in five people in the UK suffer an acute cough over the winter[@R1] and it is one of the most common reasons for consulting a general practitioner (GP), at a cost to the National Health Service (NHS) of ∼£2 billion per year.[@R2] Although most acute coughs improve spontaneously, many patients use over-the-counter (OTC) medicines. In 2014, £98.7 million was spent in the UK on OTC cough treatments.[@R5] OTC cough medicines include antitussives, expectorants, mucolytics, antihistamines, decongestants and numerous drug combinations.[@R6] There is a lack of data supporting the efficacy of OTC medicines in the treatment of acute cough associated with upper respiratory tract infection (URTI). In 2012, a Cochrane systematic review concluded there was no strong evidence for or against their effectiveness.[@R6] Methodological flaws in clinical trial design, paucity of placebo-controlled trials, use of unvalidated outcome measures and inefficacy of medicines were some of the reasons for the poor evidence base.

CS1002 is an OTC cough medicine that contains three active ingredients: diphenhydramine, levomenthol and ammonium chloride in a cocoa-based demulcent preparation. Diphenhydramine is an antihistamine that has been reported to reduce the heightened cough reflex sensitivity in participants with cough associated with an URTI.[@R7] Menthol and eucalyptus have been used for many centuries for treating coughs and colds.[@R8] Menthol is obtained from mint oils, mainly peppermint, or made synthetically from coal tar. It has a pungent odour that provides a cooling and soothing effect in the mouth and throat and is often used to relieve congestion.[@R8] Menthol has also been reported to inhibit cough reflex sensitivity compared with placebo.[@R9] Ammonium chloride is an acid-forming salt that is thought to exert an expectorant effect by loosening sputum.[@R10] The effectiveness and mode of action of ammonium chloride remains controversial.[@R10] The cocoa-based demulcent preparation used in CS1002 is more viscous than most available OTC cough medicines. Demulcents are thought to reduce cough and cold symptoms because of a soothing effect on the mucus membrane.[@R11] The aim of this study was to investigate the efficacy of CS1002, an OTC cough medicine for cough associated with URTI, in a randomised controlled trial.

Methods {#s2}
=======

Study design {#s2a}
------------

This multicentre, randomised, parallel group, controlled, single-blinded study was conducted in 4 GP surgeries and 14 pharmacies in the UK between 30 December 2014 and 9 May 2015. The control was a widely used simple linctus (SL) medicine available for acute cough in the UK. The investigators were blinded to the nature of the investigational product by using identical sealed packaging for both medicines. Participants self-administered their assigned medication outside the pharmacy or GP surgery.

Participants {#s2b}
------------

Participants aged ≥18 years who self-referred themselves to a GP or pharmacist with an acute cough of \<7 days\' duration were recruited. Participant inclusion criterion was a severity of at least 60 mm on a 0--100 mm visual analogue scale (VAS). Participant exclusion criteria were (1) participants with a chronic cough, (2) current or history of smoking within the past 12 months (including e-cigarettes), (3) participants with any relevant hospital stay of \>2 days within a 6-month period, (4) use of any cough or cold treatment for the current cough episode, including antibiotics, (5) productive cough with excessive secretion, (6) use of ACE inhibitors medication.

Participant involvement {#s2c}
-----------------------

Participants were not involved in the design or conduct of this study.

Ethics and trial registration {#s2d}
-----------------------------

The trial protocol was registered prior to starting the study in the publically available EudraCT database (reference: 2014-004255-31) and no protocol amendments were made subsequently. All participants provided written informed consent.

Randomisation {#s2e}
-------------

All participants considered eligible for study participation and who signed a consent form were given a unique randomisation number based on a predefined computer-generated randomisation scheme corresponding to a sealed medication pack that contained either CS1002 (2×150 mL) or SL (2×150 mL). Participants were allocated treatment using a block randomisation with a block size of 4.

Study medication {#s2f}
----------------

Participants were randomised to one of the following treatments: CS1002 (Unicough): diphenhydramine 14 mg/5 mL, levomenthol 1.1 mg/5 mL and ammonium chloride 135 mg/5 mL in a cocoa-based demulcent preparation.SL: citric acid monohydrate 125 mg/5 mL in a syrup base.

Interventions {#s2g}
-------------

The participants were approached, screened, consented and randomised during their initial consultation with their GP or the pharmacist. Participants took their study medication orally four times daily (5 mL in the morning, 5 mL at lunchtime, 10 mL at teatime and 10 mL at bedtime) for up to 7 days. Participants were instructed to take the medication regularly until the cough resolved.

Methods of evaluation {#s2h}
---------------------

Participants completed their assessments and compliance with medication in a daily diary. Each participant received a tamper-evident unidentifiable patient pack which was only opened on leaving the site. On completion, the pack was returned in a resealed and unidentifiable state. An independent data management organisation was used for data entry and to manage adverse event (AE) reporting. The investigators were blinded to the assignment of treatment and to the outcome assessments. The schedule of study visits is presented in [figure 1](#BMJOPEN2016014112F1){ref-type="fig"}. The participants were asked to complete assessments at baseline (day 1) and then at the same time of day from day 2--8. The study evaluated the efficacy of the study medications by assessing various aspects of acute cough.[@R12] Cough severity, frequency and impact on sleep disruption in the previous 24 hours were assessed using a VAS. Health-related quality of life (HRQoL) was assessed using the Leicester Cough Questionnaire for acute cough (LCQ-acute).[@R3] [@R13] The LCQ is a valid and reliable health status measure of acute cough in adults and is responsive to change. It comprises 19 items divided into three domains (physical, psychological and social) and uses a seven-point Likert response scale. A higher score indicates a better health status. The LCQ is designed for self-administration and takes \<5 min to complete.[@R3] [@R14]

![Study design. GP, general practitioner; LCQ-acute, Leicester Cough Questionnaire; VAS, visual analogue scale.](bmjopen2016014112f01){#BMJOPEN2016014112F1}

Primary efficacy end point {#s2i}
--------------------------

The primary efficacy end point was change from baseline to day 4 (ie, after 3 complete days of treatment) in cough severity on a 100 mm VAS (ranging from 0=no cough to 100=worst cough ever).

Secondary efficacy end points {#s2j}
-----------------------------

The following prespecified end points were evaluated: (1) change from baseline in cough severity VAS at days 6 and 8; (2) change from baseline in cough frequency and cough sleep disruption VAS at days 4, 6 and 8; (3) time to resolution of cough symptoms, defined as the day at which cough severity VAS\<17 mm (the threshold considered to be of minimal severity and the minimally important difference (MID) in acute cough);[@R12] (4) change from baseline in LCQ-acute score at days 4, 6 and 8.

Safety monitoring {#s2k}
-----------------

Participants were advised to reduce the dose of medication if they experienced drowsiness, and to document this in their daily diary. If drowsiness persisted, they were advised to discontinue the medication. Participants were advised to contact their doctor or a 24-hour help line if they felt unwell. Safety was assessed in terms of the frequency and severity of AEs occurring during the study and this was recorded by the investigator.

Statistical analysis and sample size {#s2l}
------------------------------------

The sample size calculation was based on a difference in the change in cough severity VAS of 17 mm between participants treated with CS1002 and SL. Evaluation of the VAS in acute cough has suggested that the MID is 17 mm.[@R12] It was estimated that ∼180 participants would be required to achieve a power of 90% to detect a difference between the treatment groups of 17 mm, with an SD of 35 mm.[@R12]

The primary analysis was conducted on the intention-to-treat (ITT) population, comprising all randomised participants who were treated with at least one dose of study medication and provided a baseline and at least one on-treatment assessment of cough severity. No imputation was used for missing data (ie, only observed data were used). A mixed model for repeated measures analysis was used to compare the effect of study treatments on cough parameters from baseline. The model included effects for treatment group, day, pooled centre, baseline cough severity, and treatment-by-day and baseline-by-day cough severity interaction terms. Residual plots and a normality test were used to assess normality. The results were also repeated for the per-protocol set (PPS), defined as participants in the ITT population who did not have an important protocol violation. A sensitivity analysis was also conducted to assess the robustness of the primary efficacy results to the method of handling missing data, using a last observation carried forward approach and a baseline observation carried forward approach for participants with no on-treatment data. Parametric data were presented as mean and either SD, SEM or 95% CIs. Statistical significance was defined as p≤0.05. The proportions of participants with cough resolution were compared using a stratified (by centre) Cochran-Mantel-Haenszel test. Time-to-event analysis using a Cox proportional hazards model stratified by centre was used to estimate a HR.

Results {#s3}
=======

Participants {#s3a}
------------

A total of 163 participants were randomised into the study at 4 GP sites and 14 pharmacy sites. The reasons for screening failures are shown in [figure 2](#BMJOPEN2016014112F2){ref-type="fig"}. The ITT population comprised 157 participants (82 CS1002, 75 SL), and the PPS comprised 142 participants (75 CS1002, 67 SL; [figure 2](#BMJOPEN2016014112F2){ref-type="fig"}). The baseline characteristics of both treatment groups were well matched ([table 1](#BMJOPEN2016014112TB1){ref-type="table"}). The mean age of the participants was 38 years, 57% of participants were female and 62% of participants were white (34% Asian and 4% black). The groups were well matched for the proportion of participants describing the characteristics of their cough as dry (CS1002 50%; SL 52%), chesty (CS1002 29%; SL 31%) or tickly (CS1002 21%; SL 17%).

###### 

Participant demographic and baseline characteristics

  --------------------------------------------------------------------
                                     CS1002\         Simple linctus\
                                     n (%)\          n (%)\
                                     N=82            N=75
  ---------------------------------- --------------- -----------------
  Gender (N (%))                                     

   Male                              34 (42)         34 (45)

   Female                            48 (59)         41 (55)

  Age (years)                                        

   Mean (SD)                         38.5 (17.3)     38.2 (16.6)

   Median (range)                    31.5 (18, 75)   34.0 (18, 86)

  Type of referral (N (%))                           

   GP                                30 (37)         27 (36)

   Pharmacist                        52 (63)         48 (64)

  Smoking status (N (%))                             

   Never smoked                      64 (78)         54 (72)

   Ex-smoker                         18 (22)         21 (28)

  Cough characteristics, mean (SD)                   

   Cough duration (days)             3.0 (1.5)       3.1 (1.6)

   Cough severity VAS (mm)           80.4 (10.1)     81.6 (9.9)

   Cough frequency VAS (mm)          79.5 (16.1)     76.7 (15.5)

   Cough sleep disruption VAS (mm)   75.5 (23.2)     64.6 (29.2)

  LCQ-acute scores, mean (SD)                        

   Total score                       10.8 (3.5)      11.4 (3.2)

   Physical score                    3.7 (1.2)       4.1 (1.1)

   Psychological score               3.7 (1.2)       3.9 (1.1)

   Social score                      3.4 (1.4)       3.5 (1.3)
  --------------------------------------------------------------------

Based on ITT population.

GP, general practitioner; ITT, intention-to-treat; LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale (using a scale of 0--100 mm).

![Trial CONSORT flow diagram. VAS, visual analogue scale.](bmjopen2016014112f02){#BMJOPEN2016014112F2}

Exposure {#s3b}
--------

Participants took CS1002 medication for a mean (SD) of 6.2 (2.1) days and SL medication for 6.6 (1.8) days. The mean number of doses of study medication were 22.2 (8.7) for the CS1002 group and 23.7 (8.3) in the SL group. The maximum number of medication doses possible during the study was 28. The weight of the bottles of treatment returned at the end of study was planned to be used to estimate compliance, excluding doses not taken due to early termination from the study due to recovery. The weight of medicine broadly agreed with self-reported consumption stated by participants receiving CS1002, with a mean (SD) of 94% (17%) vs 94% (18%) for participants receiving SL.

Primary efficacy end point {#s3c}
--------------------------

There was a clinically meaningful improvement in cough severity VAS at day 4 in both groups ([table 2](#BMJOPEN2016014112TB2){ref-type="table"} and [figure 3](#BMJOPEN2016014112F3){ref-type="fig"}). The magnitude of the reduction in cough severity score was greater in the CS1002 group compared with the SL group but was not statistically significant; mean (95% CI) difference of −5.9 mm (−14.4 to 2.7), p=0.18. The PPS and ITT sensitivity analyses with imputations were also consistent with this finding (see online [supplementary file](#SM1){ref-type="supplementary-material"}).
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###### 

Analysis of key efficacy parameters at day 4

  Key efficacy assessments                         CS1002                   Simple linctus
  ------------------------------------------------ ------------------------ ------------------------
  Number of participants                           82                       75
  Cough severity                                                            
   Baseline value (mean±SD)                        80.4 (10.1)              81.6 (9.9)
   Change from baseline to day 4: mean ( 95% CI)   −38.9 (−45.2 to −33.2)   −32.8 (−39.6 to −27.0)
   Adjusted mean difference (95% CI)               −5.9 (−14.4 to 2.7)      
   p Value (between groups)                        **p=0.18**               
  Cough frequency                                                           
   Baseline value (mean±SD)                        79.5 (16.1)              76.7 (15.5)
   Change from baseline to day 4: mean ( 95% CI)   −40.7 (−46.0 to −34.6)   −32.1 (−38.1 to −26.4)
   Adjusted mean difference (95% CI)               −8.1 (−16.2 to 0.1)      
   p Value (between groups)                        **p=0.05**               
  Cough resolution                                                          
   Day 4 value (n, %)                              24 (29.3%)               13 (17.3)
   Difference (%)                                  12%                      
   p Value (between groups)                        **p=0.08**               
  Sleep disruption                                                          
   Baseline value (mean±SD)                        75.5 (23.2)              64.6 (29.2)
   Change from baseline to day 4; mean ( 95% CI)   −42.8 (−46.9 to −34.4)   −26.3 (−35.5 to −22.6)
   Adjusted mean difference (95% CI)               −11.6 (−20.6 to −2.7)    
   p Value (between groups)                        **p=0.01**               

Based on intention-to-treat (ITT) population.

Negative values indicate a reduction in cough symptoms.

Adjusted mean difference, difference in between group differences. Cough severity, frequency and sleep disruption measured on a visual analogue scale (0-100 mm) Bold signifies p values.

![Change in cough severity over time. ITT, intention-to-treat.](bmjopen2016014112f03){#BMJOPEN2016014112F3}

Secondary efficacy end points {#s3d}
-----------------------------

*Cough severity*: There was a progressive decrease in cough severity VAS over the study, with the CS1002 group reporting a greater reduction compared with the SL group between days 3 and 7 ([figure 3](#BMJOPEN2016014112F3){ref-type="fig"}). The between group changes in cough severity VAS did not achieve statistical significance (mean (95% CI) difference of −4.2 mm (−12.2 to 3.9), p=0.31 at day 7; [table 2](#BMJOPEN2016014112TB2){ref-type="table"} and [figure 3](#BMJOPEN2016014112F3){ref-type="fig"}).

*Cough frequency*: There was a greater reduction in cough frequency VAS with CS1002 compared with SL at all time points ([figure 4](#BMJOPEN2016014112F4){ref-type="fig"}). At Day 4, there was an −8.1 mm (95% CI −16.2 to 0.1) greater reduction in cough frequency VAS for CS1002 compared with SL (p=0.05; [table 2](#BMJOPEN2016014112TB2){ref-type="table"} and [figure 4](#BMJOPEN2016014112F4){ref-type="fig"}).

![Change in cough frequency over time. ITT, intention-to-treat; MMRM, mixed model for repeated measures.](bmjopen2016014112f04){#BMJOPEN2016014112F4}

*Cough resolution*: By day 4, 29.3% of participants in the CS1002 group had achieved cough resolution compared with 17.3% in the SL group (p=0.08; [table 2](#BMJOPEN2016014112TB2){ref-type="table"}). There was no significant difference between the treatment groups regarding median time taken to achieve cough resolution (CS1002 6.5 days, SL 7.0 days, HR 1.300, p=0.20, [figure 5](#BMJOPEN2016014112F5){ref-type="fig"}). In a post hoc analysis, 20 participants (24.4%) in the CS1002 group and 10 (10.7%) in SL group stopped treatment by day 4 due to improvement in cough (p=0.02).

![Resolution of cough: cumulative percentage of participants. ITT, intention-to-treat; VAS, visual analogue scale.](bmjopen2016014112f05){#BMJOPEN2016014112F5}

*Sleep disruption*: There was a greater reduction in sleep disruption with CS1002 compared with SL at all time points ([figure 6](#BMJOPEN2016014112F6){ref-type="fig"}). At day 4, the magnitude of reduction in cough sleep disruption score was greater for the CS1002 group than for the SL group, mean difference of −11.6 mm (95% CI −20.6 to −2.7), p=0.01 ([figure 6](#BMJOPEN2016014112F6){ref-type="fig"} and [table 2](#BMJOPEN2016014112TB2){ref-type="table"}). A summary of all VAS results is provided in online [supplementary figure S1](#SM1){ref-type="supplementary-material"}.

![Change in cough sleep disruption over time. ITT, intention-to-treat; MMRM, mixed model for repeated measures.](bmjopen2016014112f06){#BMJOPEN2016014112F6}

*Health-related quality of life*: LCQ-acute total scores increased over time for both treatment groups, indicating an improvement in HRQoL. At day 6, the magnitude of the improvement was significantly greater in the CS1002 group compared with the SL group (mean difference 1.21 (95% CI 0.05 to 2.36), p=0.04; see online [supplementary figures S2 and S3](#SM1){ref-type="supplementary-material"}).

Adverse events {#s3e}
--------------

AEs were reported for 17 participants (20.5%) in the CS1002 group and 21 participants (27.6%) in the SL group during the study ([table 3](#BMJOPEN2016014112TB3){ref-type="table"}). The AEs were generally indicative of the study indication or likely to be associated with URTI, with the majority being mild or moderate severity. Events classified as severe were only seen in the SL treatment group, and comprised cough, sneezing and joint swelling (all occurring in one participant each). No SAEs or deaths were reported. There were no AEs of drowsiness reported during the study. Six participants (7%) in the CS1002 group and no participants in the SL group reported in their diary that they reduced the dose of medication due to drowsiness/tiredness. These events were not reported by the participants as AE. Following the reduction of the dose of medication, there were no further reports of drowsiness or tiredness.

###### 

Adverse events (AEs)

  ------------------------------------------------------------------------------------
                                                         CS1002\     Simple linctus\
                                                         N=83        N=79
  ------------------------------------------------------ ----------- -----------------
  Number of participants with an AE                      17 (20.5)   21 (27.6)

  Nervous system disorders                               7 (8.4)     10 (13.2)

   Headache                                              5 (6.0)     9 (11.8)

   Dizziness                                             1 (1.2)     2 (2.6)

  Respiratory, thoracic and mediastinal disorders        8 (9.6)     9 (11.8)

   Oropharyngeal pain                                    2 (2.4)     4 (5.3)

   Cough                                                 2 (2.4)     3 (3.9)

   Productive cough                                      3 (3.6)     1 (1.3)

   Dyspnoea                                              0 (0.0)     2 (2.6)

  Gastrointestinal disorders                             5 (6.0)     2 (2.6)

   Diarrhoea                                             3 (3.6)     0 (0.0)

   Abdominal pain upper                                  2 (2.4)     0 (0.0)

  General disorders and administration site conditions   0 (0.0)     5 (6.6)

   Pain                                                  0 (0.0)     3 (3.9)

   Fever                                                 0 (0.0)     2 (2.6)

  Infections and infestations                            1 (1.2)     2 (2.6)

   Lower respiratory tract infection                     0 (0.0)     2 (2.6)
  ------------------------------------------------------------------------------------

Treated set population. AEs reported for \>1 participant.

Discussion {#s4}
==========

This multicentre, randomised study compared the efficacy and safety of two OTC cough mixtures: CS1002 containing diphenhydramine, ammonium chloride and levomenthol in a cocoa-based demulcent preparation versus SL containing citric acid monohydrate. This is one of the largest multiple dosing, randomised controlled trials in participants with URTI-associated cough to date, and the first to recruit participants seeking cough medicines at pharmacies. The study did not achieve a significant reduction in primary end point cough severity after 3 days of treatment, but there were greater reductions in cough frequency and sleep disruption and resolution of cough in participants receiving CS1002 compared with SL.

Our trial represents a significant advance in the study of URTI-associated cough for a number of reasons. A Cochrane systematic review of cough medicines concluded that there was no evidence for or against cough medicines for URTI-associated cough.[@R6] Previous trials of cough medicines have been hampered by the recruitment of small numbers of participants, the recruitment of participants not representative of URTI-associated cough, uncontrolled study design and the use of unvalidated end points. We conducted a randomised clinical trial that included validated cough outcome measures. Our primary outcome measure, the VAS, is widely used in studies of cough.[@R15] We recruited participants with an URTI-associated cough who were otherwise healthy and seeking an antitussive medicine. Our participants were unselected for the category of cough, and included a broad range of participants with self-reported dry, chesty and tickly cough. We conducted a large study, recruiting participants from 18 sites. This is the first study to recruit participants presenting to pharmacies, and therefore the study population is more likely to resemble the broader population seeking cough medicines. There were few participants that dropped out of the trial, and therefore our data completeness was good. The efficacy of the interventions was evaluated with widely used and validated end points of cough severity VAS and LCQ-acute HRQoL questionnaires.[@R15] [@R16] We conducted a controlled trial and the comparator was a widely used OTC treatment. SL, which costs less than many OTC medicines to purchase but like most cough medicines, it lacks a strong evidence base. Its efficacy has not been compared with natural recovery, placebo or to other cough medicines. The rate of reduction of cough severity VAS associated with SL in our study does appear to be greater than that reported for natural recovery.[@R12] The mechanism of action of SL is poorly understood, but is thought to be related to a demulcent effect and the hypersalivation resulting from the sugary taste.[@R11]

There was a clinically significant reduction in primary end point cough severity VAS at day 4 in both groups. However, CS1002 did not achieve the primary end point of a greater reduction in cough severity at day 4 compared with SL. There were, however, greater reductions in secondary end points of sleep disruption and cough frequency, and improvements in HRQoL associated with CS1002 compared with SL. There was also a trend favouring greater resolution of cough at day 4 with CS1002 compared with SL, with a near doubling of the proportion of participants whose cough had resolved. This was supported by a post hoc analysis that found a significantly greater number of participants had discontinued their medication due to resolution of cough by day 4 (CS1002, 24.4% vs SL, 10.7%: p=0.02). The MID for cough outcome measures of frequency VAS, sleep disruption VAS and cough resolution have not been reported in URTI-associated cough, and this should be studied in future to facilitate the clinical interpretation of data. CS1002 was well tolerated, and there were few significant AEs, including drowsiness. Drowsiness was managed with dose reduction, and no participants discontinued the medication because of this symptom. Participants were compliant with both medications, and this was verified by counting the doses of medication returned at the end of the study. The mechanism of action of CS1002 is poorly understood. There are a number of possibilities, which include a reduction in cough reflex sensitivity,[@R7] promotion of more restful sleep and a demulcent action. CS1002 contains a cocoa-flavoured demulcent that is more viscous than most available OTC cough medicines, and this may potentially promote palatability.

There are a number of important limitations with our study. We did not use a placebo comparator, and the study was not double-blinded. The limitations of a single-blinded study were reduced by informing the participants that they were going to receive a cough medicine, but not the characteristics of the medicine. The investigators were blinded to the study because both medicines were contained in identical packaging, and participants were instructed to start their medication outside the pharmacy or GP clinic. We used SL as the comparator since this is a widely used cough treatment. It is possible that there may have been greater differences in efficacy outcome measures if we had used an inactive placebo. Another option for comparator that should be considered in future studies is the demulcent used in CS1002. It is likely that there was also significant natural recovery in our study. Our data highlight the difficulty in evaluating cough medicines in a rapidly resolving condition. We do not know whether the cough at study entry was worsening or improving and this could have impacted on our findings. We were short of our recruitment target of 180 participants; we recruited 163 participants. This was due to a delay in the start of the study, and consequently a reduced time window for recruitment during the cough and cold winter season. We think it is unlikely that the slight under-recruitment of participants would have altered our study conclusions. The reasons for screen failures were not recorded for many patients, particularly at busy pharmacy sites. The reasons were, however, recorded for 2238 participants and suggest that a large number of participants approached had duration of cough \>7 days. It is possible that the discontinuation of medication could have reflected lack of efficacy as well as recovery. We did not investigate the cause of the acute cough, and future studies should possibly assess viruses, pertussis and bacterial causes. We did not assess cough with objective outcome measures, such as cough frequency monitoring.[@R16] Recently, there have been significant advances in cough monitoring technology, and this should be possible in future studies.[@R17]

In conclusion, the OTC cough medicine CS1002 did not achieve a significant reduction in the primary end point cough severity, but it was associated with a greater reduction in cough frequency and sleep disruption, and increased resolution of cough leading to early discontinuation of medication and improved HRQoL compared with comparator SL. Further studies should investigate the impact of natural recovery and placebo on cough outcome measures to facilitate the optimal study protocol in URTI-associated cough.
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